Market Risers: Applied Graphene Materials, AstraZeneca, British Land Company, CRH

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

Shares of Applied Graphene Materials ticker lookup code: LON:AGM has gained 15% or 1.43 points in today’s trading session so far. Traders have remained positive throughout the trading session. The periods high figure was 11 meanwhile the session low reached 9. The total volume of shares exchanged so far has reached 235,327 with the daily average at 114,711. A 52 week share price high is 35 equating to 25.5 points difference from the previous close and the 52 week low at 7 a difference of some 2.5 points. Applied Graphene Materials now has a 20 simple moving average of 9.93 and now its 50 day simple moving average now of 9.98. The market capitalisation is now £5.40m at the time of this report. All share prices mentioned for this stock are traded in GBX. Mcap is measured in GBP. This article was written with the last trade for Applied Graphene Materials being recorded at Friday, May 29, 2020 at 12:42:53 PM GMT with the stock price trading at 10.93 GBX.

The trading price for AstraZeneca company symbol: LON:AZN has climbed 2.39% or 208 points throughout the session so far. Buyers have so far held a positive outlook throughout the session. The period high was 8990 while the low for the session was 8788. The total volume of shares traded by this point was 929,452 with the daily average traded share volume around 2,314,757. The 52 week high price for the shares is 9335 some 637 points difference from the previous days close and the 52 week low at 5739 which is a variance of 2959 points. AstraZeneca now has a 20 SMA of 8830.89 and now its 50 day simple moving average now at 8083.56. The current market capitalisation is £116,960.12m at the time of this report. Share price is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for AstraZeneca being recorded at Friday, May 29, 2020 at 1:18:26 PM GMT with the stock price trading at 8906 GBX.

Shares in British Land Company found using EPIC: LON:BLND has increased 2.47% or 9.8 points during today’s session so far. Buyers have remained positive while the stock has been in play. The period high has peaked at 411.2 and hitting a low of 386.2. The volume total for shares traded up to this point was 2,872,040 while the average shares exchanged is 6,364,143. The stock 52 week high is 649.4 which comes in at 252.2 points difference from the previous days close and putting the 52 week low at 309.4 which is a variance of 87.8 points. British Land Company now has a 20 simple moving average of 376.01 and now the 50 day MA at 378.27. Market capitalisation is now £3,777.16m at the time of this report. The currency for this stock is Great British pence.Market cap is measured in GBP. This article was written with the last trade for British Land Company being recorded at Friday, May 29, 2020 at 1:22:08 PM GMT with the stock price trading at 407 GBX.

Stock in CRH EPIC code: LON:CRH has climbed 1.78% or 47 points during today’s session so far. Market buyers seem confident during this period. The high for the period has reached 2695 while the low for the session was 2603. The amount of shares exchanged has so far reached 949,647 with the daily average traded share volume around 2,128,107. A 52 week share price high is 3116 equating to 471 points in difference to the previous days close of business and a 52 week low sitting at 1500 a difference of some 1145 points. CRH now has a 20 SMA at 2445.22 with a 50 day MA at 2329. Market capitalisation is now £21,153.33m at the time of this report. Share price is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for CRH being recorded at Friday, May 29, 2020 at 1:20:06 PM GMT with the stock price trading at 2692 GBX.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
AstraZeneca's Imfinzi receives FDA approval for limited-stage small cell lung cancer, marking a significant breakthrough in extending patient survival.
AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint.

Search

Search